Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Docetaxel plus Gemcitabine as First-line Treatment in Malignant Pleural Mesothelioma: A Single Institution Phase II Study

MARIA RALLI, IOANNIS TOURKANTONIS, NEKTARIA MAKRILIA, ELENI GKINI, ELIAS KOTTEAS, IOANNIS GKIOZOS, NIKOLAOS KATIRTZOGLOU and KOSTAS SYRIGOS
Anticancer Research August 2009, 29 (8) 3441-3444;
MARIA RALLI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rallh79@yahoo.gr
IOANNIS TOURKANTONIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NEKTARIA MAKRILIA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ELENI GKINI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ELIAS KOTTEAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IOANNIS GKIOZOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NIKOLAOS KATIRTZOGLOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOSTAS SYRIGOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 29 no. 8 3441-3444
PubMed 
19661370

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received March 30, 2009
  • Revision received May 29, 2009
  • Accepted June 4, 2009
  • Published online August 6, 2009.

Copyright & Usage 
Copyright© 2009 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. MARIA RALLI,
  2. IOANNIS TOURKANTONIS,
  3. NEKTARIA MAKRILIA,
  4. ELENI GKINI,
  5. ELIAS KOTTEAS,
  6. IOANNIS GKIOZOS,
  7. NIKOLAOS KATIRTZOGLOU and
  8. KOSTAS SYRIGOS
  1. Oncology Unit GPP, Sotiria General Hospital, Athens School of Medicine, Athens, Greece
  1. Correspondence to: Maria Ralli, MD, Oncology Unit, 3rd Department of Medicine, Athens University School of Medicine, Building Z, Sotiria General Hospital, Mesogion 152, 115 27 Athens, Greece. Tel: +30 2107475034, Fax: +30 2107781035, e-mail: rallh79{at}yahoo.gr
View Full Text

Cited By...

  • 14 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Anticancer Research: 29 (8)
Anticancer Research
Vol. 29, Issue 8
August 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Docetaxel plus Gemcitabine as First-line Treatment in Malignant Pleural Mesothelioma: A Single Institution Phase II Study
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Docetaxel plus Gemcitabine as First-line Treatment in Malignant Pleural Mesothelioma: A Single Institution Phase II Study
MARIA RALLI, IOANNIS TOURKANTONIS, NEKTARIA MAKRILIA, ELENI GKINI, ELIAS KOTTEAS, IOANNIS GKIOZOS, NIKOLAOS KATIRTZOGLOU, KOSTAS SYRIGOS
Anticancer Research Aug 2009, 29 (8) 3441-3444;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Docetaxel plus Gemcitabine as First-line Treatment in Malignant Pleural Mesothelioma: A Single Institution Phase II Study
MARIA RALLI, IOANNIS TOURKANTONIS, NEKTARIA MAKRILIA, ELENI GKINI, ELIAS KOTTEAS, IOANNIS GKIOZOS, NIKOLAOS KATIRTZOGLOU, KOSTAS SYRIGOS
Anticancer Research Aug 2009, 29 (8) 3441-3444;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
  • Mesothelioma Interactome with 367 Novel Protein-Protein Interactions
  • Google Scholar

More in this TOC Section

  • The Systemic Inflammation Score Is an Independent Prognostic Factor for Esophageal Cancer Patients who Receive Curative Treatment
  • Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma
  • Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2022 Anticancer Research

Powered by HighWire